Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort

Cancer Management and Research

Volumn 3, Issue 1, 2011, Pages 201-209

  David Crawford, E ^a   Phillips, Jason M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

6 month depot; Leuprolide; Leuprorelin; Prostate cancer; Testosterone; Triptorelin

Indexed keywords

LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIPTORELIN;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BURNING SENSATION; CANCER PALLIATIVE THERAPY; CANCER STAGING; CASTRATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HOT FLUSH; HUMAN; INJECTION SITE REACTION; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS POTENTIAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION;

EID: 80955136887     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Prostate Cancer Foundation. Report to the Nation on Prostate Cancer 2004. Available at: http://www.medscape.org/viewcollection/30050. Accessed January 6, 2011.
2. Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2006;175:533-536.
3. Palmberg C, Koivisto P, Visakorpi T, Tammela T. PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol. 1999;36:191-196.
4. Cox MC, Scripture CD, Figg WD. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain? Expert Rev Anticancer Ther. 2005;5:605-611.
5. Sharifi R, Bruskewitz RC, Gittleman MC, Graham SD Jr, Hudson PB, Stein B. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther. 1996;18: 647-657.
6. Lundström EA, Rencken RK, van Wyk JH, et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clin Drug Investig. 2009;29:757-765.
7. Huggins C, Hodges C. Studies on prostate cancer: the effect of castration, estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-297.
8. Sethi R, Sanfilippo N. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. Clin Interv Aging. 2009;4: 259-267.
9. Amo FH. Comparative analysis of six months formulation of LHRH analogues for prostate cancer treatment. Arch Esp Urol. 2010;63: 275-281.
10. Schally AV, Arimura A, Baba Y, et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun. 1971; 43:393-399.
11. Fujino M, Fukuda T, Shinagawa S, Kobayashi S, Yamazaki I. Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10. Biochem Biophys Res Commun. 1974;60: 406-413.
12. Monahan MW, Amoss MS, Anderson HA, Vale W. Synthetic analogs of the hypothalamic luteinizing hormone releasing factor with increased agonist or antagonist properties. Biochemistry. 1973;12:4616-4620.
13. Chrisp P, Sorkin EM. Leuprorelin: a review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging. 1991;1:487-509.
14. Anderson J, Abrahamsson PA, Crawford D, Miller K, Tombal B. javascript: AL_get(this, 'jour', 'BJU Int.'); Management of advanced prostate cancer: can we improve on androgen deprivation therapy? BJU Int. 2008;101:1497-501.
15. Millar RP, Troskie BE, Flanagan CA. Comparative receptor binding aff inity and inositol phosphate production potency of D-Leu6 and D-Trp6 GnRH agonists on COS-1 cells transfected with the human GnRH receptor. XIII International Congress of Comparative Endocrinology. 1997:559-562.
16. Miller K, Anderson J, Abrahamsson P-A. Treatment of prostate cancer with hormonal therapy in Europe. BJU Int. 2009;103(Suppl 2): 2-6.
17. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer v.2.2009. Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed December 9, 2009.
18. N. [Pharmacokinetics and pharmacodynamics of triptorelin]. Ann Urol (Paris). 2005;39(Suppl 3):78-84. French.
19. Coy DH, Vilchez-Martinez JA, Coy EJ, et al. Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. J Med Chem. 1976;19: 423-425.
20. Barron JL, Miller RP, Searle D. Metabolic clearance and plasma halfdisappearance time of D-TRP6 and exogenous luteinizing hormonereleasing hormone. J Clin Endocrinol Metab. 1982;54:1169-1173.
21. Müller FO, Terblanchè J, Schall R, et al. Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. Br J Clin Pharmacol. 1997;44: 335-341.
22. Sennello LT, Finley RA, Chu SY, et al. Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. J Pharm Sci. 1986;75:158-160.
23. Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet. 2002;41:485-504.
24. Lee M, Browneller R, Wu Z, Jung A, Ratanawong C, Sharifi R. Therapeutic effects of leuprorelin microspheres in prostate cancer. Adv Drug Deliv Rev. 1997;28:121-138.
25. Akaza H, Usami M, Koiso K, Kotake T, Aso Y, Niijima T. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group. Jpn J Clin Oncol. 1992;22:177-184.
26. Fowler JE, Flanagan M, Gleason DM, Klimberg IW, Gottesman JE, Sharifi R. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer. Urology. 2000;55:639-642.
27. Fowler JE Jr, Gottesman JE, Reid CF, Andriole GL Jr, Soloway MS. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J Urol. 2000;164(3 Pt 1): 730-734.
28. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56:1021-1024.
29. Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol. 2007;178(4 Pt 1):1290-1295.
30. Tunn UW, Bargelloni U, Cosciani S, Fiaccavento G, Guazzieri S, Pagano F. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. Urol Int. 1998;60(Suppl 1):9-16; discussion 16-17.
31. Sharifi R, Knoll LD, Smith J, Kramolowsky E. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer. Urology. 1998;51:271-276.
32. Perez-Marreno R, Chu FM, Gleason D, Loizides E, Wachs B, Tyler RC. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther. 2002;24:1902-1914.
33. Chu FM, Jayson M, Dineen MK, Perez R, Harkaway R, Tyler RC. A clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2002;168:1199-1203.
34. Sartor O, Dineen MK, Perez-Marreno R, Chu FM, Carron GJ, Tyler RC. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology. 2003;62:319-323.
35. Marberger M, Kaisary AV, Shore ND, et al. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. Clin Ther. 2010;32:744-757.
36. Clinical study report. Comparative testosterone pharmacodynamics and therapeutic efficacy of 1- and 3-month formulations of triptorelin pamoate in patients with advanced prostate cancer. DEB-96- TR1-01 (first phase). Lausanne, Switzerland: Debiopharm SA; 1999.
37. Morote J, Esquena S, Abascal JM, et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int. 2006;77:135-138.
38. Sarosdy MF, Schellhammer PF, Soloway MS, et al. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int. 1999;83:801-806.
39. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol. 2000;164(3 Pt 1):726-729.
40. Wechsel HW, Zerbib M, Pagano F, Coptcoat MJ. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol. 1996;30(Suppl 1):7-14.
41. D. Leuprorelin 3-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results. Urol Int. 1998;60(Suppl 2):18-24; discussion 35.
42. Thompson IM. Flare Associated with LHRH-Agonist Therapy. Rev Urol. 2001;3(Suppl 3):S10-S14.
43. Bubley GJ. Is the flare phenomenon clinically significant? Urology. 2001;58(2 Suppl 1):5-9.
44. Eligard 225 mg: leuprolide acetate for injectable suspension [package insert]. Sanofi-aventis; 2004.
45. Eligard 30 mg: leuprolide acetate for injectable suspension [package insert]. Sanofi-aventis; 2004.
46. R, Browneller R; Leuprolide Study Group. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol. 2002;168:1001-1004.
47. Khan MS, O'Brien A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int. 1998;60:33-40.
48. Fontana D, Mari M, Martinelli A, et al. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. Urol Int. 2003;70:316-320.
49. Horwich A, Parker C, Kataja V. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl 2):45-46.
50. National Institute for Health and Clinical Excellence. Prostate cancer: diagnosis and treatment. Available at: http://www.nice.org.uk/nicemedia/live/11924/39687/39687.pdf. Accessed January 7, 2011.
51. Moretti RM, Monagnani Marelli M, van Groeninghen JC, Motta M, Limonta P. Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression. Endocr Relat Cancer. 2003;10:161-167.
52. D'Amico AV, Manola J, Loffredo M, Renshaw AA, Della Croce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821-827.
53. Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol.2001;166:500-5006; discussion 506-507.
54. Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes. 2007;14: 247-254.
55. De Jong IJ, Eaton A, Bladou F. LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion. Curr Med Res Opin. 2007;23:1077-1080.
56. Waxman JH, Wass JA, Hendry WF, et al. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J (Clin Res Ed). 1983;286:1309-1312.
57. Mcleod DG. Hormonal therapy: historical perspective to future directions. Urology. 2003;61(2 Suppl 1):3-7.
58. Bergquist C, Nillius SJ, Bergh T, Skarin G, Wide L. Inhibitory effects on gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue. Acta Endocrinol (Copenh). 1979;91:601-608.
59. Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology. 1995;46:220-226.
60. Sharifi R, Soloway M; Leuprolide Study Group. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol. 1990;143:68-71.
61. Sharifi R, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238-244.
62. E, Lübben G; German Leuprorelin Study Group. Efficacy and safety of leuprorelin acetate depot for prostate cancer. Urol Int. 1996;56(Suppl 1):23-30.
63. Persad R. Leuprorelin acetate in prostate cancer: a European update. Int J Clin Pract. 2002;56:389-396.
64. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. Cancer J Clin. 2002;52:154-179.
65. Whelan P. Triptorelin embonate: a 6-month formulation for prostate cancer. Expert Opin Pharmacother. 2010;11:2929-2932.
66. Pathak AS, Pacificar JS, Shapiro CE, Williams SG. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study. J Urol. 2007;177: 2132-2135; discussion 2135.
67. Greil S, Robinson EA, Singal B, Kleer E. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals. Urology. 2009;73: 631-634.
68. Shore ND, Crawford ED. Intermittent androgen deprivation therapy: redefining the standard of care? Rev Urol. 2010;12:1-11.
69. Calais da Silva FEC, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009;55:1269-1277.